Investigations › GLP-1 era
Investigation No. 10 · GLP-1 era
“GLP-1 causes muscle loss, so avoid it”
Lean mass does come off with the fat. The size of it is an open question, and the response to the concern is not avoidance.
At a glance
- Verdict
- Partly true
- Certainty in the evidence
- Low, starting at High and moved by 2 domains
- Evidence base
- Systematic review: 19 studies found, 2 poolable for muscle · 2 studies read
- Last reviewed
- 11 Sept 2026
- Next review due
- Mar 2027
How people actually say it
- “I’ve heard these drugs eat your muscle.”the most legitimate concern in this group
- “You lose forty percent of it as lean mass.”a number with almost nothing under it
Why this verdict and not the next one
Partly true rather than mixed, because the direction is not in doubt and only the magnitude is. The ‘so avoid it’ half is where it fails, since lifting and protein answer the concern without avoidance.
Where the claim came from
From a real finding, amplified by an industry with a stake in the answer. The fitness and supplement worlds have both genuine expertise in muscle and a commercial position that a medication threatens.
What the studies did
A 2026 systematic review searched three databases from inception and found nineteen studies. Pooling those with a control group left two for muscle, reported as too imprecise to be useful. Muscle quality could not be pooled at all. Separately, Longland and colleagues showed in a randomized trial that higher protein during an energy deficit with intense exercise produced greater lean mass gain and greater fat loss than lower protein.
Why these papers and not others
The 2026 review was chosen over any individual study, because it searched three databases from inception and reports what it could not pool. Longland is included as the mechanism for the response, and is flagged as not being a GLP-1 study.
The full search and appraisal protocol, including what gets excluded and why, is set out in the method.
The evidence, study by study
| Study | Design | n | What it found | What it cannot say |
|---|---|---|---|---|
| Lopes Menezes 2026 | Systematic review, three databases from inception | 2 poolable | 19 studies found, 2 controlled studies poolable for muscle, result reported as too imprecise to be useful | The magnitude everybody is quoting |
| Longland 2016 | Randomized trial, energy deficit plus intense exercise | 40 | Higher protein produced greater lean mass gain and greater fat loss than lower protein | Whether it transfers to people on a GLP-1, since none were |
How the certainty grade was reached
Certainty starts at a level set by the study design, then moves down for every domain that fails a written threshold and up for every domain that clears one. The arithmetic is shown rather than asserted.
What the evidence cannot say
Any of the percentages in circulation. A quarter, a third, forty percent: ask where each came from and what it was compared against. Several come from single-arm studies with no control group.
One person, worked through
A 68-year-old starts a GLP-1 and reads that it eats muscle. She is already unsteady on stairs, so her concern is more warranted than a 35-year-old’s. The answer is still not avoidance: it is measuring strength directly with a grip test or a sit-to-stand count, and getting the lifting and the protein in from the start rather than after.
Whether this applies to you
A verdict is a reading of a population. Whether it describes you depends on the things below, and any one of them can change what the right move is for you.
- Age more than anything else here, because sarcopenia risk rises steeply
- Starting muscle mass which sets how much there is to lose
- Existing frailty or recent illness which belongs with the prescriber rather than a web page
What would change this entry
Controlled studies measuring muscle rather than lean mass, reporting function as well as composition, following older adults specifically.
Read this before you act on it
This is an appraisal of published evidence, not medical or nutrition advice, and it is not a substitute for care from a clinician who knows your history, your medications and your labs. Nothing here is a diagnosis, a prescription or a treatment plan, and reading it does not create a clinician and patient relationship.
Do not start, stop or change a medication, a supplement or a diet on the strength of this page. If you are pregnant, breastfeeding, managing kidney or liver disease, diabetes, an eating disorder or any chronic condition, the general reading above may not describe you at all. Talk to your physician or a registered dietitian first.
The verdict above was true to the evidence on 11 Sept 2026. Evidence moves. Check the review date.
References
- Lopes Menezes ML et al. Diabetes Obes Metab. 2026 Aug 17. PMID 42608323. · Longland TM et al. Am J Clin Nutr. 2016;103(3):738–746. PMID 26817506.
